我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
1
批准总数
监管机构
监管机构数
成立时间
1975
暂无试验阶段数据
暂无试验数据
SFDA
Saudi Food and Drug Authority
- Mikart and Nano PharmaSolutions reported positive interim Phase 1 safety and pharmacokinetic data for NT-301, a proprietary powder nasal spray targeting Parkinson's disease OFF episodes. - The nanodrug delivery system demonstrated dose-proportional exposure and rapid absorption with Tmax of approximately 20 minutes in healthy volunteers across 1-3 mg doses. - NT-301 utilizes NanoTransformer® technology, a patented platform that enhances drug solubility and bioavailability through nano-coating of active pharmaceutical ingredients. - Companies are expanding manufacturing capabilities for the NanoTransformer® platform to meet anticipated demand as clinical development progresses.
